![]() We knew that at least over that range, lower LDL-C was better. There was neither regression nor progression with the high-dose atorvastatin, but there was clear cut, unequivocal progression with the LDL-C at 110 mg/dL (2.84 mmol/L) with pravastatin. We achieved an LDL-C of 110 mg/dL (2.84 mmol/L) with a dose of 40 mg of pravastatin and 79 mg/dL (2.04 mmol/L) with 80 mg of atorvastatin. We felt differently, and so we designed the REVERSAL trial. That was based upon a post hoc analysis of the CARE trial. ![]() The argument had been made by a number of people, particularly in Boston, that lowering LDL-C below 125 mg/dL had no incremental benefit. When we started this work in the late 1990s, there was a raging debate.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |